Quarterly ResultMay 11, 2026, 04:20 PM
Erasca Q1 Net Loss $183.4M; Joyo License Expanded, Novartis Program Terminated
AI Summary
Erasca, Inc. reported a net loss of $183.4 million for Q1 2026, significantly higher than the $31.0 million loss in Q1 2025, primarily due to a $150.0 million in-process research and development expense. This expense was incurred for exercising an option to expand its exclusive license agreement with Joyo Pharmatech to include mainland China, Hong Kong, and Macau for pan-RAS inhibitors. Concurrently, Erasca decided to stop development of its naporafenib program and terminated its license agreement with Novartis Pharma AG. The company also completed an underwritten offering in January 2026, raising $242.7 million in net proceeds.
Key Highlights
- Exercised option to expand Joyo License Agreement territory for $150.0 million.
- Terminated Novartis Agreement for naporafenib program, effective June 3, 2026.
- Reported Q1 2026 net loss of $183.4 million, up from $31.0 million in Q1 2025.
- Incurred $150.0 million in-process R&D expense in Q1 2026 related to Joyo license.
- Completed January 2026 underwritten offering, raising $242.7 million net proceeds.
- Cash, cash equivalents, and marketable securities totaled $408.5 million as of March 31, 2026.
- Net cash used in operating activities was $27.4 million in Q1 2026.
- Total stockholders' equity increased to $393.5 million from $325.2 million at Dec 31, 2025.